Inhibitor Therapeutics, Inc. (INTI) AI Dilution Summary

The disclosed funding posture is cash of $515,758 at the last reported balance-sheet date, 2026-06-30, against estimated monthly burn of $309,956. No instrument in the disclosed terms carries a variable-rate, VWAP-linked or reset conversion, so the ranking falls to the fixed-price tier: equity-plan awards outstanding account for the whole 990,000 potential new shares, equal to 0.6% of the 173,791,968 shares outstanding.